Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (5994)	11/20/1998 4:27:00 PM
From: Biomaven	Respond to of 9719

MODEL SELLS 272 SEPR @ $80 1/8 Taking a little profit, we still like the long term on this one, but feel we can buy it back in early '99 cheaper. I forgot - you get to deal with Fantasy IRS as well as Fantasy Brokerage. <G> SEPR sure has had a nice run-up here on not much new news. They don't seem very leaky, so I suspect it is just more analysts seeing the light, rather than a Prozac deal or the like. However I suspect (with no real concrete basis) there's more good news waiting in the wings, so I respectfully hope you are wrong about buying it cheaper next year. Peter

To: Rocketman who wrote (5994)	11/20/1998 9:37:00 PM
From: Vector1	Read Replies (2) \| Respond to of 9719

Yes, I am back on the net. Don't ask. You were so efficient with the emails I sent you from 40,000 feet that we got hit on SEPR. I love the stock and didn't think we would get a jump like that. if it went up 4 points I would have raised the target. All in all I think we will get a correction to 70 which is where we should buy it back. I could get talked into 75. I love the stock. the development risk is low and the potential is enormous. However they are arrogent SOBs. Market is incredibly strong and the I Banks are again talking about biotech IPOs. Unbelievable. Have you ever seen such a quick 360. Asia is still quite sick by the way. i would be very careful in 99. The world economy has a lot of risk and Y2K could hurt a number of companies earnings. I lifted the sale price on AGPH because Rick posted on the AGPH thread that the Lancet is coming out with a positive comments on Remmune. If Remmune is approvable AGPH is a monster. Rumor is that the company is being shopped but that they are looking for a big time price (North of 60) If Remmune is sucessful 60 is nothing. v1

To: Rocketman who wrote (5994)	11/23/1998 10:40:00 PM
From: RCMac	Respond to of 9719

>>feel we can buy [SEPR] back in early '99 cheaper.<< Well, maybe -- SEPR has come a long way very quickly. But maybe not. SEPR has said a couple of times recently that it is actively discussing licensing or co-promotion deals for several of its ICE's, and expects to sign up one more deal by year end. One of the links is: techstocks.com If they do announce a deal in the near term, particularly if that deal is with Lilly for SEPR's ICE for Prozac, SEPR will surely be up another 10 or 15 points in a couple of days, and the hope of seeing the 60's or even the 70's again may be gone. I suspect that holding onto SEPR rather than hoping for a lower reentry point is the safer thing to do. (It's what I've done, even though I've had a part of my position long enough to pay capital gains tax rates.) This is a stock you don't want to miss the upside on. BTW, great call on the ENMD short, Rman. Good analysis, great timing. (Recall that 10 or12 years ago, several guys went to jail for too neatly anticipating WSJ "Heard on the Street" columns, including the writer of the column. If you were playing with real money here, you might be expecting an SEC knock at your door. <g>) I think you're plainly right to take profits on the ENMD short, though -- I thought at first you were right that the stock would go much lower, but the investing public has apparently discounted the criticisms set out in the WSJ article (I suppose mistrusting the press like the public mistrusts the press on the Monica scandal), so there may not be any movement until the next news. -- RCM